Impact of Immigration Status on Survival Among Stage 1 and 2 HER2 ‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada
Cancer Medicine · 2025
DOI: 10.1002/cam4.71288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Omolara Fatiregun und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Emigrants and Immigrants, Emigration and Immigration. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Health, Ministry of Long-Term Care.
Abstract (Originalsprache)
Background
This study examined death from breast cancer and death from other causes among women with Stage 1 and 2 Her2‐positive and triple‐negative breast cancer (BC) by immigration status.
Methods
We identified women aged 18–75 diagnosed with BC in Ontario from January 1, 2012, to December 31, 2019, followed them to December 31, 2023, and identified legal immigrants from the Immigration, Refugee, and Citizenship Canada Permanent Resident (CIC) database. We linked administrative data sources for the date of diagnosis, molecular subtype, death due to breast cancer, and death due to all other causes. Using adjusted competing risks regression (Fine and Gray method), we analyzed the influence of immigration on breast cancer survival and calculated the sub‐distribution hazard ratios (sHR).
Results
There was no increased risk of death among legal immigrants on univariate or multivariable analysis. They had a sHR of 0.95 (0.77–1.19) on univariate analysis and 1.06 (95% CI: 0.83–1.36) on multivariable analysis for breast cancer deaths, and for other causes of death, 0.63 (0.47–0.83) on univariate analysis, and 0.85 (95% CI: 0.62–1.15) on multivariable analysis compared to long‐term residents. Patients with HER2‐positive status had a lower risk of death from breast cancer and other causes compared to those with triple‐negative breast cancer (TNBC). Patients with Stage 2 cancer had a significantly higher hazard of death from breast cancer compared to Stage 1 (HR = 3.72, 95% CI: 2.96–4.66, p < 0.0001).
Conclusions
In Ontario, legal immigrants do not have an increased risk of death from breast cancer or other causes compared to long‐term residents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
- Department of Radiology (Clinical Oncology), Lagos State University College of Medicine, Lagos, Nigeria.
- Institute for Clinical Evaluative Sciences (ICES), Toronto, Ontario, Canada.
- Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
- Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, Toronto, Ontario, Canada.
- Department of Medicine, Sunnybrook Health Science Centre, Toronto, Ontario, Canada.
ORCID-Profile: Omolara Fatiregun, Rinku Sutradhar
Förderung
- Ministry of Health
- Ministry of Long-Term Care
Zitieren
APA
Fatiregun, O., Sutradhar, R., Podolsky, S., Eisen, A., Paszat, L., & Rakovitch, E. (2025). Impact of Immigration Status on Survival Among Stage 1 and 2 HER2 ‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada. Cancer Medicine. https://doi.org/10.1002/cam4.71288
Vancouver
Fatiregun O, Sutradhar R, Podolsky S, Eisen A, Paszat L, Rakovitch E. Impact of Immigration Status on Survival Among Stage 1 and 2 HER2 ‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada. Cancer Medicine. 2025. doi:10.1002/cam4.71288
BibTeX
@article{Fatiregun2025,
author = {Fatiregun, Omolara and Sutradhar, Rinku and Podolsky, Sho and Eisen, Andrea and Paszat, Lawrence and Rakovitch, Eileen},
title = {Impact of Immigration Status on Survival Among Stage 1 and 2 HER2 ‐Positive and Triple‐Negative Breast Cancer in Ontario, Canada},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71288}
}
EUVIMED